

CSD/NSE&BSE/AR2025

August 28, 2025

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001  
**Scrip Code: 543064**

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: COHANCE**

Dear Sir/ Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Please note that in terms of the provisions of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclosed herewith the letter being issued to shareholders whose e-mail address is not registered with the Company / RTA / Depository Participants, providing the weblink from where the Annual Report of the Company for the financial year 2024-25 can be accessed on the Company's website.

You are requested to take the above information on your record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

Encl: as above

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)





**Cohance Lifesciences Limited**

(Formerly Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, 2nd Floor, Galaxy Towers, Plot No.1,  
Hyderabad Knowledge City, TSIC Raidurg, Hyderabad, Telangana 500081

Tel: +91 40 23549414; Email: [investorservices@suvenpharm.com](mailto:investorservices@suvenpharm.com)

Website: <https://suvenpharm.com>; CIN: L24299MH2018PLC422236

Date: August 26, 2025

Folio No. / DP Id Client Id : [REDACTED]

Dear Shareholder,

**Sub: Web-link of the Annual Report for the Financial Year ended March 31, 2025**

We are pleased to inform you that the 7th Annual General Meeting (AGM) of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited) ("the Company") is scheduled to be held on Friday, September 19, 2025 at 2.30 p.m. (IST) through Video Conference (VC) / Other Audio-Visual Means (OAVM), in compliance with the various circulars issued by MCA and SEBI from time to time.

The Notice of the 7th AGM along with the Annual Report for the financial year 2024-25 is being sent by electronic mode to Members whose e-mail ids are registered with the Company/ Registrar & Share Transfer Agent (RTA) or the Depository Participants (DPs).

In terms of the provisions of Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, in the absence of your email id registered with the RTA / Depository Participant, this letter is being sent to you to provide the web-link including the path to access the Annual Report of Company, which is given below:

**Web-link:** [https://www.suvenpharm.com/pdf/Investors/Financial-Info/Cohance\\_AnnualReport\\_2025.pdf](https://www.suvenpharm.com/pdf/Investors/Financial-Info/Cohance_AnnualReport_2025.pdf)

**Path:** [www.suvenpharm.com](http://www.suvenpharm.com) > Investors > Financial Info > FY2025 > Annual Reports > Annual Report 2025

As per SEBI guidelines, it is mandatory for shareholders to update their PAN, KYC details (including postal address with pin code, email address, mobile number, bank account details), and nomination details. We request you to update your KYC and submit the required documents/information to your respective Depository Participant / RTA at [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com) at the earliest convenience. Furthermore, any payments, including dividends, for folios where PAN or KYC details are not updated, will only be made electronically upon the registration of the required information.

We would also like to draw attention of our shareholders to Senior Citizens Investor Cell which has been formed by our RTA to assist exclusively the shareholders who are senior citizens (above 60 years of age) in redressing their grievances, complaints and queries. The senior citizens wishing to avail this service can send the communication to [senior.citizen@kfintech.com](mailto:senior.citizen@kfintech.com). A dedicated toll-free number 1800 3094 006 is also provided for the convenience of the senior citizens

We appreciate your prompt attention to this letter.

For any queries or further assistance, please reach out to the RTA at [einward.ris@kfintech.com](mailto:einward.ris@kfintech.com).

Thanking you.

Yours faithfully,

For **Cohance Lifesciences Limited**

(Formerly, Suven Pharmaceuticals Limited)

Sd/-

**Kundan Kumar Jha**

*Company Secretary, Compliance Officer and Head-Legal*